Revvity (RVTY) Stock Price
Revvity Price
Over the last 19 years Revvity grew revenue by 3.3% annually, reaching 2.86 B USD. Earnings per share have grown at 4.5% per year over the last 19 years. For Revvity, the net margin of 8.5% is down versus 24.6% a few years ago. At today's price the dividend yield works out to roughly 0.22%. The payout ratio is around 13% of earnings. The consensus 12-month price target for Revvity is 118.83 USD, about 4.7% below where the stock trades today. Of 26 analysts, 15 rate the stock a buy — an overall Buy consensus. The stock trades about 52% above its 52-week low.
Revvity stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Revvity over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Revvity stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Revvity's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Revvity Price |
|---|---|
| 8/21/2026 | 124.75 USD |
| 8/20/2026 | 124.13 USD |
| 8/19/2026 | 120.33 USD |
| 8/18/2026 | 115.15 USD |
| 8/14/2026 | 116.84 USD |
| 8/13/2026 | 117.50 USD |
| 8/12/2026 | 117.88 USD |
| 8/11/2026 | 115.73 USD |
| 8/10/2026 | 115.60 USD |
| 8/7/2026 | 114.66 USD |
| 8/6/2026 | 114.24 USD |
| 8/5/2026 | 114.58 USD |
| 8/4/2026 | 111.67 USD |
| 8/3/2026 | 115.22 USD |
| 7/31/2026 | 112.52 USD |
| 7/30/2026 | 113.54 USD |
| 7/29/2026 | 110.97 USD |
| 7/27/2026 | 109.54 USD |
| 7/23/2026 | 113.17 USD |
| 7/22/2026 | 110.54 USD |
| 7/21/2026 | 110.52 USD |
| 7/20/2026 | 106.44 USD |
| 7/17/2026 | 110.15 USD |
| 7/16/2026 | 111.70 USD |
| 7/15/2026 | 111.35 USD |
| 7/14/2026 | 111.21 USD |
| 7/13/2026 | 112.03 USD |
| 7/10/2026 | 112.29 USD |
| 7/9/2026 | 112.95 USD |
| 7/8/2026 | 110.65 USD |
| 7/7/2026 | 112.05 USD |
| 7/6/2026 | 112.00 USD |
| 7/2/2026 | 113.76 USD |
| 7/1/2026 | 112.84 USD |
| 6/30/2026 | 111.26 USD |
| 6/29/2026 | 111.39 USD |
| 6/26/2026 | 113.02 USD |
| 6/25/2026 | 113.53 USD |
| 6/24/2026 | 105.63 USD |
| 6/23/2026 | 99.90 USD |
| 6/22/2026 | 99.24 USD |
| 6/18/2026 | 98.48 USD |
| 6/17/2026 | 99.37 USD |
| 6/16/2026 | 100.65 USD |
| 6/15/2026 | 100.69 USD |
| 6/12/2026 | 100.70 USD |
| 6/11/2026 | 99.78 USD |
| 6/10/2026 | 104.01 USD |
| 6/9/2026 | 104.13 USD |
| 6/8/2026 | 100.30 USD |
| 6/5/2026 | 98.89 USD |
| 6/4/2026 | 103.52 USD |
| 6/3/2026 | 101.47 USD |
| 6/2/2026 | 99.55 USD |
| 6/1/2026 | 103.56 USD |
| 5/29/2026 | 101.95 USD |
| 5/28/2026 | 101.18 USD |
| 5/27/2026 | 96.72 USD |
| 5/26/2026 | 95.86 USD |
| 5/22/2026 | 94.95 USD |
| 5/21/2026 | 94.80 USD |
| 5/20/2026 | 94.97 USD |
| 5/19/2026 | 95.87 USD |
| 5/18/2026 | 95.48 USD |
| 5/15/2026 | 93.97 USD |
| 5/14/2026 | 96.38 USD |
| 5/13/2026 | 95.01 USD |
| 5/12/2026 | 99.30 USD |
| 5/11/2026 | 98.95 USD |
| 5/8/2026 | 101.00 USD |
| 5/7/2026 | 98.85 USD |
| 5/6/2026 | 99.09 USD |
| 5/5/2026 | 92.30 USD |
| 5/4/2026 | 86.51 USD |
| 5/1/2026 | 86.68 USD |
| 4/30/2026 | 86.62 USD |
| 4/29/2026 | 82.26 USD |
| 4/28/2026 | 85.18 USD |
| 4/27/2026 | 86.80 USD |
| 4/24/2026 | 86.77 USD |
| 4/23/2026 | 87.15 USD |
| 4/22/2026 | 94.28 USD |
| 4/21/2026 | 94.27 USD |
| 4/20/2026 | 93.03 USD |
| 4/17/2026 | 93.96 USD |
| 4/16/2026 | 89.53 USD |
| 4/15/2026 | 92.90 USD |
| 4/14/2026 | 93.51 USD |
| 4/13/2026 | 92.64 USD |
| 4/10/2026 | 89.79 USD |
| 4/9/2026 | 90.46 USD |
| 4/8/2026 | 90.40 USD |
| 4/7/2026 | 87.79 USD |
| 4/6/2026 | 88.32 USD |
| 4/2/2026 | 88.94 USD |
| 4/1/2026 | 87.92 USD |
| 3/31/2026 | 87.61 USD |
| 3/30/2026 | 84.78 USD |
| 3/27/2026 | 83.90 USD |
| 3/26/2026 | 87.12 USD |
| 3/25/2026 | 87.84 USD |
| 3/24/2026 | 87.46 USD |
| 3/23/2026 | 87.16 USD |
| 3/20/2026 | 85.94 USD |
| 3/19/2026 | 85.76 USD |
| 3/18/2026 | 85.76 USD |
| 3/17/2026 | 87.37 USD |
| 3/16/2026 | 86.48 USD |
| 3/13/2026 | 85.57 USD |
| 3/12/2026 | 84.76 USD |
| 3/11/2026 | 89.63 USD |
| 3/10/2026 | 90.30 USD |
| 3/9/2026 | 92.11 USD |
| 3/6/2026 | 91.34 USD |
| 3/5/2026 | 96.57 USD |
| 3/4/2026 | 98.49 USD |
| 3/3/2026 | 95.95 USD |
| 3/2/2026 | 95.59 USD |
| 2/27/2026 | 98.31 USD |
| 2/26/2026 | 99.01 USD |
| 2/25/2026 | 97.57 USD |
| 2/24/2026 | 97.62 USD |
| 2/23/2026 | 97.12 USD |
| 2/20/2026 | 100.33 USD |
| 2/19/2026 | 99.91 USD |
| 2/18/2026 | 97.74 USD |
| 2/17/2026 | 95.01 USD |
| 2/13/2026 | 96.03 USD |
| 2/12/2026 | 95.57 USD |
| 2/11/2026 | 101.10 USD |
| 2/10/2026 | 104.75 USD |
| 2/9/2026 | 102.82 USD |
| 2/6/2026 | 101.59 USD |
| 2/5/2026 | 99.52 USD |
| 2/4/2026 | 103.83 USD |
| 2/3/2026 | 101.13 USD |
| 2/2/2026 | 107.09 USD |
| 1/30/2026 | 108.80 USD |
| 1/29/2026 | 108.49 USD |
| 1/28/2026 | 108.86 USD |
| 1/27/2026 | 114.61 USD |
| 1/26/2026 | 114.70 USD |
| 1/23/2026 | 116.73 USD |
| 1/22/2026 | 117.75 USD |
| 1/21/2026 | 116.53 USD |
| 1/20/2026 | 111.90 USD |
| 1/16/2026 | 112.50 USD |
| 1/15/2026 | 115.33 USD |
| 1/14/2026 | 111.52 USD |
| 1/13/2026 | 110.14 USD |
| 1/12/2026 | 109.01 USD |
| 1/9/2026 | 104.43 USD |
| 1/8/2026 | 101.71 USD |
| 1/7/2026 | 102.99 USD |
| 1/6/2026 | 105.05 USD |
| 1/5/2026 | 102.06 USD |
| 1/2/2026 | 98.15 USD |
| 12/31/2025 | 96.75 USD |
| 12/30/2025 | 97.43 USD |
| 12/29/2025 | 97.11 USD |
| 12/26/2025 | 96.75 USD |
| 12/24/2025 | 96.78 USD |
| 12/23/2025 | 97.58 USD |
| 12/22/2025 | 97.77 USD |
| 12/19/2025 | 96.24 USD |
| 12/18/2025 | 96.26 USD |
| 12/17/2025 | 96.77 USD |
| 12/16/2025 | 96.27 USD |
| 12/15/2025 | 99.08 USD |
| 12/12/2025 | 100.49 USD |
| 12/11/2025 | 103.92 USD |
| 12/10/2025 | 103.51 USD |
| 12/9/2025 | 98.78 USD |
| 12/8/2025 | 99.79 USD |
| 12/5/2025 | 100.79 USD |
| 12/4/2025 | 102.55 USD |
| 12/3/2025 | 103.26 USD |
| 12/2/2025 | 102.73 USD |
| 12/1/2025 | 102.43 USD |
| 11/28/2025 | 104.41 USD |
| 11/26/2025 | 104.66 USD |
| 11/25/2025 | 105.57 USD |
| 11/24/2025 | 100.58 USD |
| 11/21/2025 | 98.27 USD |
| 11/20/2025 | 94.02 USD |
| 11/19/2025 | 92.25 USD |
| 11/18/2025 | 93.06 USD |
| 11/17/2025 | 91.06 USD |
| 11/14/2025 | 92.73 USD |
| 11/13/2025 | 93.40 USD |
| 11/12/2025 | 94.13 USD |
| 11/11/2025 | 94.31 USD |
| 11/10/2025 | 92.28 USD |
| 11/7/2025 | 90.78 USD |
| 11/6/2025 | 89.52 USD |
| 11/5/2025 | 92.57 USD |
| 11/4/2025 | 91.69 USD |
| 11/3/2025 | 92.97 USD |
| 10/31/2025 | 93.59 USD |
| 10/30/2025 | 91.02 USD |
| 10/29/2025 | 95.30 USD |
| 10/28/2025 | 96.45 USD |
| 10/27/2025 | 97.16 USD |
| 10/24/2025 | 99.51 USD |
| 10/23/2025 | 97.57 USD |
| 10/22/2025 | 95.68 USD |
| 10/21/2025 | 96.89 USD |
| 10/20/2025 | 95.31 USD |
| 10/17/2025 | 93.72 USD |
| 10/16/2025 | 94.00 USD |
| 10/15/2025 | 92.12 USD |
| 10/14/2025 | 91.14 USD |
| 10/13/2025 | 90.98 USD |
| 10/10/2025 | 88.24 USD |
| 10/9/2025 | 91.66 USD |
| 10/8/2025 | 91.77 USD |
| 10/7/2025 | 91.19 USD |
| 10/6/2025 | 93.38 USD |
| 10/3/2025 | 94.01 USD |
| 10/2/2025 | 91.46 USD |
| 10/1/2025 | 91.52 USD |
| 9/30/2025 | 87.65 USD |
| 9/29/2025 | 84.20 USD |
| 9/28/2025 | 84.20 USD |
| 9/25/2025 | 84.06 USD |
| 9/24/2025 | 83.04 USD |
| 9/23/2025 | 85.71 USD |
| 9/22/2025 | 86.27 USD |
| 9/19/2025 | 86.73 USD |
| 9/18/2025 | 87.76 USD |
| 9/17/2025 | 85.39 USD |
| 9/16/2025 | 85.28 USD |
| 9/15/2025 | 84.00 USD |
| 9/12/2025 | 83.50 USD |
| 9/11/2025 | 85.68 USD |
| 9/10/2025 | 82.50 USD |
| 9/9/2025 | 85.04 USD |
| 9/8/2025 | 86.28 USD |
| 9/5/2025 | 86.63 USD |
| 9/4/2025 | 85.70 USD |
| 9/3/2025 | 83.36 USD |
| 9/2/2025 | 87.87 USD |
| 8/29/2025 | 90.11 USD |
| 8/28/2025 | 89.23 USD |
| 8/27/2025 | 88.59 USD |
| 8/26/2025 | 91.23 USD |
| 8/25/2025 | 91.94 USD |
| 8/22/2025 | 94.36 USD |
Revvity Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Revvity Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| DIVIDENDDIV.USD |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.10 | 2.12 | 2.26 | 2.78 | 2.88 | 3.78 | 3.83 | 3.31 | 2.75 | 2.76 | 2.86 | 2.85 | 3.00 | 3.19 | 3.37 | 3.52 |
| -5.95 | 0.52 | 6.67 | 23.14 | 3.78 | 31.18 | 1.19 | -13.48 | -16.94 | 0.18 | 3.67 | -0.21 | 5.37 | 6.09 | 5.81 | 4.39 |
| 44.20 | 45.96 | 45.61 | 45.03 | 44.85 | 52.62 | 59.60 | 53.16 | 48.07 | 47.99 | 53.08 | 53.08 | 53.08 | 53.08 | 53.08 | 53.08 |
| 0.93 | 0.97 | 1.03 | 1.25 | 1.29 | 1.99 | 2.28 | 1.76 | 1.32 | 1.32 | 1.52 | 1.51 | 1.59 | 1.69 | 1.79 | 1.87 |
| 0.27 | 0.31 | 0.30 | 0.37 | 0.41 | 0.96 | 1.34 | 0.78 | 0.40 | 0.41 | 0.36 | 0.54 | 0.57 | 0.60 | 0.64 | 0.67 |
| 12.64 | 14.42 | 13.48 | 13.32 | 14.05 | 25.28 | 35.01 | 23.59 | 14.51 | 14.88 | 12.46 | 18.95 | 18.95 | 18.93 | 18.96 | 18.95 |
| 212.00 | 233.00 | 113.00 | 238.00 | 227.00 | 728.00 | 943.00 | 569.00 | -118.00 | 295.00 | 241.00 | 607.00 | 667.00 | 734.00 | 797.00 | 857.00 |
| 34.18 | 9.91 | -51.50 | 110.62 | -4.62 | 220.70 | 29.53 | -39.66 | -120.74 | -350.00 | -18.31 | 151.87 | 9.88 | 10.04 | 8.58 | 7.53 |
| 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | – | – |
| 112.56 | 110.14 | 110.36 | 111.61 | 111.63 | 112.54 | 126.72 | 126.48 | 123.43 | 121.58 | 113.21 | 113.21 | 113.21 | 113.21 | 113.21 | 113.21 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Revvity generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Revvity retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Revvity's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Revvity has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Revvity's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Revvity stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Revvity Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Revvity business model & stock analysis
Revvity SWOT Analysis
Strengths
1. Strong market presence: PerkinElmer Inc has established itself as a leading player in the scientific research and diagnostics sector, with a wide range of products and services.
2. Technological expertise: The company possesses advanced technologies and innovative solutions, giving it a competitive edge in the market.
3. Diversified product portfolio: PerkinElmer offers a diverse range of products across various segments, including life sciences, diagnostics, environmental testing, and food safety.
Weaknesses
1. Dependence on key customers: PerkinElmer relies heavily on a few large customers for a significant portion of its revenue, which exposes it to potential risks if any of these customers reduce their business or switch to competitors.
2. High research and development costs: Developing and maintaining advanced technologies requires substantial investments, which may strain the company's financial resources.
Opportunities
1. Growing demand for diagnostics: The increasing prevalence of diseases and the need for early detection and accurate diagnosis provide a significant growth opportunity for PerkinElmer in the diagnostics market.
2. Expansion in emerging markets: PerkinElmer can explore untapped markets in developing countries, leveraging its expertise to cater to the rising demand for scientific research and diagnostics solutions.
3. Acquisitions and partnerships: Strategic acquisitions or partnerships with complementary companies can help PerkinElmer expand its product offerings and broaden its customer base.
Threats
1. Intense competition: The scientific research and diagnostics market is highly competitive, with numerous established players and new entrants. PerkinElmer must continually innovate to stay ahead.
2. Regulatory challenges: Changes in regulations and compliance requirements can affect the company's operations, potentially leading to increased costs or barriers to market entry.
3. Economic downturns: Global economic uncertainties and recessions can impact the demand for PerkinElmer's products and services, as customers may reduce spending on research and diagnostics.
Revvity Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Revvity Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Revvity historical P/E ratio, EBIT multiple, and P/S ratio
Revvity annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Revvity shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Revvity Dividend History
37 years of dividend payments
Revvity dividend history and estimates
Max
Details
Revvity dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Revvity forecasts and price targets in August 2026
Analyst Price Targets 2026Revvity Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/5/2026 | Maintained | Outperform | 62 | |
| 7/6/2026 | Maintained | Outperform | 62 | |
| 5/7/2026 | Maintained | Equal Weight | 56 | |
| 5/6/2026 | Maintained | Buy | 58 | |
| 5/6/2026 | Maintained | Hold | 56 | |
| 5/6/2026 | Maintained | Neutral | 61 | |
| 5/4/2026 | Maintained | Outperform | 56 | |
| 4/14/2026 | Maintained | Neutral | 51 | |
| 4/14/2026 | Downgrade | OverweightEqual Weight | 56 | |
| 3/31/2026 | Maintained | Neutral | 61 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Revvity Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/4/2026 | 1.25USD | - | 723.86 MUSD | - | 2026 Q2 |
| 5/5/2026 | 1.04USD | - | 717.86 MUSD | - | 2026 Q1 |
| 2/2/2026 | 1.58USD | - | 776.64 MUSD | - | 2025 Q4 |
| 5/9/2024 | 1.04USD | - | 660.53 MUSD | - | 2024 Q1 |
| 2/12/2024 | 1.17USD | - | 683.14 MUSD | - | 2023 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Revvity stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Revvity shareholder structure
| % | Name |
|---|---|
19.57878% | |
8.89942% | |
7.76227% | |
7.36296% | |
6.46497% | |
6.39476% |
Revvity Beneficial Ownership Filings (SEC 13D/G)
Revvity Executives and Management Board
15 members · avg. age 58 · 33 % women
Dr. Prahlad Singh (60)
President, Chief Executive Officer, Director · since 2016
11.93 M USD
Management
Mr. Joel Goldberg (56)
Senior Vice President - Administration, General Counsel, Secretary
Mr. Maxwell Krakowiak (35)
Chief Financial Officer, Senior Vice President
Ms. Miriame Victor (44)
Chief Commercial Officer, Senior Vice President
Mr. Tajinder Vohra (59)
Senior Vice President - Global Operations
Mrs. Anita Gonzales (49)
Vice President, Controller
Board of Directors
Mr. Alexandros Michas (67)
Independent Non-Executive Chairman of the Board
Dr. Sophie Vandebroek (63)
Independent Director
Mr. Michael Klobuchar (49)
Independent Director
Mr. Samuel Chapin (67)
Independent Director
Dr. Peter Barrett (72)
Independent Director
Mr. Michel Vounatsos (63)
Independent Director
Frequently asked questions about Revvity
PerkinElmer Inc. is a company that focuses on providing products and services in the fields of diagnostics, life sciences, and applied services. Their business model revolves around offering innovative solutions for the healthcare and scientific community. With a wide range of product offerings, including instruments, reagents, consumables, software, and services, PerkinElmer Inc. aims to support scientific research, drug discovery, and diagnostics. By leveraging their expertise in detecting and analyzing biological and environmental challenges, the company strives to enable its customers to improve human and environmental health. PerkinElmer Inc.'s commitment to delivering advanced solutions makes it a trusted partner in the life sciences industry.
PerkinElmer Inc is primarily active in the scientific research and diagnostics industries.
PerkinElmer Inc faces competition from various companies in the market. Some of the main competitors of PerkinElmer Inc include Thermo Fisher Scientific Inc, Agilent Technologies Inc, Waters Corporation, and Bio-Rad Laboratories Inc. These companies also operate in the life science and analytical instrument industries, providing similar products and services. However, PerkinElmer Inc maintains a strong position in the market, leveraging its technological advancements, product innovation, and customer-centric approach to stay competitive in the industry.
PerkinElmer Inc is a highly recognized company in the field of diagnostics, life science research, and applied services. With a rich history dating back to 1937, PerkinElmer Inc has established itself as a global leader in providing innovative solutions to the scientific community. The company's commitment to improving human and environmental health is evident through its extensive range of products, technologies, and services. PerkinElmer Inc actively collaborates with research institutions, pharmaceutical companies, and government agencies to deliver cutting-edge solutions for various scientific challenges. Continuously evolving and expanding, PerkinElmer Inc remains dedicated to driving advancements and enabling breakthrough discoveries in the realms of health, safety, and environmental sustainability.
PerkinElmer Inc has accomplished several significant milestones throughout its history. With over 80 years of experience, the company has become a global leader in providing scientific solutions and technologies. Some notable achievements include the development of innovative diagnostic tools that have revolutionized healthcare, the continuous expansion of its product offering to various industries, and strategic partnerships with leading organizations. PerkinElmer Inc has also received recognition for its commitment to sustainability and social responsibility. These achievements have solidified PerkinElmer Inc's reputation as a trusted provider of high-quality scientific products and services, driving its continuous growth in the market.
PerkinElmer Inc is primarily present in various countries and regions worldwide. As a global leader in life sciences and diagnostics, PerkinElmer has a strong presence in North America, Europe, Asia Pacific, and Latin America. The company operates in over 150 countries, serving customers in academic institutions, government organizations, pharmaceutical companies, and research laboratories. With its expansive reach, PerkinElmer aims to provide innovative solutions and technologies to support advancements in human and environmental health across international borders.
PerkinElmer Inc is a leading global company that specializes in providing innovative solutions for diagnostics, life sciences, and applied services. The company aims to improve the health and well-being of people worldwide through its advanced technologies and scientific expertise. PerkinElmer Inc is committed to delivering reliable and accurate results to its customers, ensuring high-quality products and services. The company's corporate philosophy revolves around promoting sustainability, diversity, and social responsibility. With a strong focus on research and development, PerkinElmer Inc continually strives to drive technological advancements in various industries, making it a trusted leader in its field.
Analysts currently set an average price target of 120.44 USD for the Revvity stock (median: 118.83 USD), implying -3.5 % versus the latest price. The consensus is based on 26 analyst ratings.
26 analysts currently rate the Revvity stock: 15 recommend buying, 10 holding and 1 selling. For 2026, analysts expect Revvity to generate revenue of 2.85 B USD and earnings per share of 5.36 USD.
Converted at the current exchange rate, the Revvity share trades at 106.79 EUR (124.75 USD).
The Revvity share (RVTY) is listed on 7 stock exchanges, including: NYSE (PKI), Frankfurt (PKN.F), München (PKN.MU), Düsseldorf (PKN.DU), London (0KHE.L), London (0KHE.L), SIX (Zürich) (PKN.SW).
PerkinElmer Inc. is an internationally operating company specializing in the provision of products and services in the fields of life sciences, diagnostics, environmental analysis, and other related markets. The company is headquartered in Waltham, Massachusetts and employs over 13,000 employees worldwide. PerkinElmer offers a wide range of products and services tailored to the needs of its customers. In the field of life sciences, PerkinElmer focuses on researching drug candidates to develop new therapeutics and diagnostic methods. The company offers a variety of instruments, software, and reagents that support laboratory analysis. Diagnostics is another important business area for PerkinElmer. In this area, the company provides products that are tailored to the needs of end consumers. This includes devices for prenatal diagnostics, in-house laboratory diagnostics, and tests in the field of genetic diseases. Another core area of PerkinElmer is environmental analysis. PerkinElmer has a long history in the development and manufacture of instruments and consumables used to identify environmental pollutants and other similar influences. The product range includes chromatography equipment, mass spectrometers, reactive chemicals, and software solutions. PerkinElmer is also active in the field of food analysis. This includes products for the identification of food allergens, analysis of nutritional aspects, and residues of pesticides and other pollutants. Another division involves supporting customers with technical support, such as installation and commissioning of instruments, application questions, and the development of test methods. PerkinElmer also offers research and development services tailored to the needs of its customers. These services include the validation of test methods, testing for the detection of pollutants, and the introduction of automation solutions in the production process. PerkinElmer has expanded its business model to fully meet the needs of its customers. The company builds on its strong expertise and history to offer high-quality products and services. Due to its wide range of products and services, PerkinElmer has expanded into several international markets. The company strives to initiate acquisitions and mergers to continuously expand its business areas. The geographical expansion efforts are primarily focused on Asian countries and other emerging markets. Thanks to its broad product range, targeted services, and international presence, PerkinElmer can make a significant contribution to meeting the requirements and needs of its customers.
The expected revenue of Revvity is 2.85 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Revvity is 607.21 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Revvity is currently 23.26. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Revvity stock.
The price-to-sales ratio (P/S) of Revvity is currently 4.95. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Revvity stock.
The Eulerpool Quality Score for Revvity is 1/10.
The ISIN of Revvity is US7140461093. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Revvity is 850943. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Revvity is RVTY. The ticker symbol is used to trade Revvity shares on the stock exchange.
Over the past 12 months, Revvity paid a dividend of 0.28 USD . This corresponds to a dividend yield of about 0.22 %. For the coming 12 months, Revvity is expected to pay a dividend of 0.28 USD.
The current dividend yield of Revvity is 0.22 %.
Revvity pays a dividend, distributed in the months of , , , .
Revvity paid dividends every year for the past 36 years.
For the upcoming 12 months, dividends amounting to 0.28 USD are expected. This corresponds to a dividend yield of 0.22 %.
Revvity is assigned to the 'Health' sector.
To receive the latest dividend of Revvity from amounting to 0.07 USD, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
In the year 2025, Revvity distributed 0.28 USD as dividends.
The dividends of Revvity are distributed in USD.
Revvity stock
Revvity Peer Group
Revvity Ticker
Revvity FIGI
All fundamentals and in-depth analysis of Revvity
Our stock analysis for Revvity stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Revvity. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.